Rhythm Pharmaceuticals, Inc.
RYTMNASDAQHealthcare● Active
$85.93
$-0.48(-0.55%)
Market Cap$5.9B
P/E Ratio—
52W High$122.2
52W Low$60.7
Rhythm Pharmaceuticals, Inc.（RYTM）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · RYTM · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.20B) | ($0.26B) | ($0.18B) | ($0.18B) | ($0.07B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.07B | $0.04B | $0.03B | $0.02B | $0.02B |
| Change in Working Capital | ($0.00B) | $0.01B | $0.00B | ($0.02B) | $0.00B |
| Net Cash from Operations | ($0.12B) | ($0.11B) | ($0.14B) | ($0.17B) | ($0.15B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | ($0.01B) |
| Purchases of Investments | ($0.35B) | ($0.27B) | ($0.35B) | ($0.25B) | ($0.52B) |
| Sales of Investments | $0.25B | $0.26B | $0.35B | $0.28B | $0.36B |
| Net Cash from Investing | ($0.14B) | ($0.05B) | ($0.01B) | $0.03B | ($0.06B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | ($0.01B) | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.22B | $0.19B | $0.07B | $0.21B | $0.17B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.12B) | ($0.11B) | ($0.14B) | ($0.18B) | ($0.15B) |
| FCF Margin %(computed) | -61.46% | -87.51% | -175.91% | -751.79% | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Rhythm Pharmaceuticals, Inc.
关于Rhythm Pharmaceuticals, Inc.（RYTM）现金流量表
Rhythm Pharmaceuticals, Inc. 2025财年经营活动现金流($0.12B)，自由现金流($0.12B)（FCF利润率-61.46%），资本支出($0.00B)。
常见问题
RYTM · 4 问Rhythm Pharmaceuticals, Inc. 2025财年自由现金流($0.12B)，同比down2.4%。
RYTM free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10